Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ

April 28, 2021 updated by: University Medical Centre Maribor

Comparison of Conservative Treatment of Cervical Intraepithelial Lesions With Imiquimod With Standard Excisional Technique Using LLETZ: a Randomized Controlled Trial

Purpose: There are limited data on the success of conservative treatment of high-grade cervical squamous intraepithelial lesions (HSIL) with imiquimod directly compared to standard of treatment with LLETZ. LLETZ as standard treatment is possibly associated with premature labour, higher subfertility rate and a higher rate of spontaneous abortion. Since premature delivery is one of the most important causes of perinatal morbidity and mortality, alternative conservative methods for SIL treatment are constantly being evaluated. The immunomodulator imiquimod is one of the main target compounds for treating HSIL.

Primary objective: to establish the efficacy of treatment with imiquimod (experimental arm) and compare it to the standard treatment with LLETZ (control arm).

Secondary objective:

  • incidence and severity of the side effects in both groups;
  • need for treatment with LLETZ two years after primary treatment with imiquimod in the experimental arm or re-treatment with LLETZ two years after primary treatment with LLETZ in the control arm;
  • modulatory effect of imiquimod on immunoregulatory molecules.

Study design: Single-centre randomized controlled intervention trial.

Study population: 104 women with HSIL (52 in each arm).

Intervention:

- randomization in two arms:

  1. Experimental arm (imiquimod): treatment for 16 weeks with 5% imiquimod.
  2. Control arm (LLETZ).

Successful treatment in the experimental arm is defined as absence of histological HSIL in diagnostic biopsies at 20-week follow-up (4 weeks after treatment completion) and in the control arm successful treatment is defined as absence of cytological HSIL in cytology 6 months after LLETZ (same as in our national guidelines).

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Imiquimod is one of the target topical drugs for treating HSIL. It is a Toll-like receptor 7 agonist that acts locally so that it induces cellular response, which can aid in the regression of HPV-associated lesions. Imiquimod is currently used for treating genital warts. In vitro studies have shown promising effects in the treatment of several diseases, such as endometrial, cervical and prostate cancer, endometriosis, melanoma, and cervical and vulvar intraepithelial lesions. Clinical studies are however lacking. With this in mind, the aim of our study was to evaluate whether topical treatment of HSIL with imiquimod is comparable to standard treatment with LLETZ. As mentioned in the Brief summary, we have set different outcome measures in the experimental and control arm. The different outcome measures were based on moderate accuracy of PAP smear, therefore in order to minimize potential progression of cervical disease to cancer and to avoid LLETZ and possible overtreatment and to assess as accurately as possible the potential residual disease, colposcopy with biopsies will be performed 4 weeks after treatment with imiquimod is completed (20th week after treatment initiation). Follow up after LLETZ will performed using cytology (PAP smear), which is in concordance with our national guidelines. Biopsies will be performed in case of clinically visible lesions. Secondary outcomes of the study are the incidence and severity of the side effects in both groups, which will be evaluated during and after treatment using the 5th version of the Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Other secondary outcomes, namely the need for treatment with LLETZ two years after primary treatment with imiquimod in the experimental arm or re-treatment with LLETZ two years after primary treatment with LLETZ in the control arm, respectively, and the modulatory effect of imiquimod on immunoregulatory molecules are expected to be available in three years' time after treatment is completed in all patients in both arms.

Study Type

Interventional

Enrollment (Actual)

104

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Slovenia
      • Maribor, Slovenia, 2000
        • University Medical Centre Maribor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • newly diagnosed and previously untreated HSIL in women aged 18 to 35 years or up to 40 years in case of nulliparity;
  • satisfactory colposcopy (i.e., fully visible lesion and transformation zone);
  • negative pregnancy test;
  • safe contraception;
  • signed, informed consent.

Exclusion Criteria:

  • previously diagnosed HSIL or AIS;
  • previous LLETZ or classical conisation;
  • concomitant vulvar or vaginal lesion or neoplasia;
  • other malignancies;
  • insufficient colposcopy;
  • pregnancy or lactation;
  • known hypersensitivity to imiquimod;
  • any known contraindications to immunotherapy;
  • known HIV or acute or chronic hepatitis;
  • immune deficiency;
  • participation in any other ongoing clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment with imiquimod
Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
Drug: Aldara 5% Topical Cream
5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
Other Names:
  • Zyclara, imiquimod
Active Comparator: Treatment with LLETZ
Standard treatment will be scheduled after patients' first period.
Procedure: LLETZ
LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
Other Names:
  • LEEP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment efficacy of 5% imiquimod cream for treatment of HSIL compared to standard treatment with LLETZ defined as absence of HSIL in both arms (histological in experimental arm and cytological in control arm).
Time Frame: 20 weeks after treatment initiation in experimental arm and 6 months after LLETZ in control arm.

Defined as following:

  • for experimental (imiquimod) treatment arm: absence of histological HSIL (CIN1 or less) in diagnostic biopsies at colposcopy at 20 weeks;
  • for control (LLETZ) arm: absence of cytological HSIL at 6 months follow-up.
20 weeks after treatment initiation in experimental arm and 6 months after LLETZ in control arm.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence and severity of the side effects in both arms.
Time Frame: 10 weeks and 20 weeks after treatment initiation in experimental arm and 20 weeks after LLETZ in control arm.
Incidence and severity of side effects scored by the 5th version of the Common Terminology Criteria for Adverse Events (CTCAE) guidelines.
10 weeks and 20 weeks after treatment initiation in experimental arm and 20 weeks after LLETZ in control arm.
Need for LLETZ or repeated LLETZ following primary treatment.
Time Frame: 2 years after primary treatment.
The need for treatment with LLETZ two years after primary treatment with imiquimod in the experimental arm or re-treatment with LLETZ two years after primary treatment with LLETZ in the control arm
2 years after primary treatment.
Immunoregulatory effect of imiquimod.
Time Frame: 2 years after primary treatment.
Modulatory effect of imiquimod on immunoregulatory molecules.
2 years after primary treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Medical Centre Maribor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2018

Primary Completion (Actual)

April 21, 2020

Study Completion (Anticipated)

September 15, 2023

Study Registration Dates

First Submitted

April 21, 2021

First Submitted That Met QC Criteria

April 23, 2021

First Posted (Actual)

April 26, 2021

Study Record Updates

Last Update Posted (Actual)

May 3, 2021

Last Update Submitted That Met QC Criteria

April 28, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2017-01-02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intraepithelial Neoplasia, Cervical

Clinical Trials on Aldara 5% Topical Cream

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe